Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study) (ConCoVid-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04342182
Recruitment Status : Recruiting
First Posted : April 10, 2020
Last Update Posted : May 18, 2020
Sponsor:
Collaborator:
Sanquin Plasma Products BV
Information provided by (Responsible Party):
Bart Rijnders, Erasmus Medical Center

Brief Summary:

Passive immunization with immunoglobulins is occasionally used as therapy for the treatment of viral infectious diseases. Immunoglobulins are used for the treatment of CMV disease, and is effective as prophylaxis when given soon after exposure to varicella zoster virus, rabies, and hepatitis B virus.

Neutralizing antibodies against MERS, SARS-CoV-1 and SARS-CoV-2 have been shown to be present in patients previously infected with MERS, SARS-CoV-1 and SARS-CoV-2 respectively. During the 2003 SARS outbreak in Hong-Kong,a non-randomized study in hospitalized SARS patients showed that treatment with convalescent plasma (convP) from SARS-recovered donors significantly increased the day 22 discharge rate and decreased mortality. A study in non-human primates showed that rhesus macaques could not be re-infected with SARS-CoV-2 after primary infection.

With no proven effective therapy against COVID, this study will evaluate the safety and efficacy of convalescent plasma from COVID-recovered donors as a treatment for hospitalized patients with symptomatic COVID-19. The study will focus on patients who tested positive for SARS-CoV-2 in the last 96 hours before inclusion

Primary objectives

• Decrease overall mortality in patients within COVID disease

Study design:

This trial is a randomized comparative trial. Patients will be randomized between the infusion of 300mL of convP with standard of care.

Patient population:

Patients with PCR confirmed COVID disease, age >18 years Donors will be included with a known history of COVID who have been asymptomatic for at least 14 days.

Intervention: 300mL of convP Duration of treatment: ConvP will be given as a one-time infusion Duration of follow up: For the primary endpoint: until discharge or death before day 60, whichever comes first. For the secondary endpoints (with separate consent) up to 1 year.

Target number of patients: 426 Target number of donors: 100 Expected duration of accrural: 36 months


Condition or disease Intervention/treatment Phase
COVID-19 Biological: Convalescent plasma Phase 2 Phase 3

Detailed Description:

Secondary (exploratory) objectives

  • Evaluate the effect of 300ml convP on hospital stay
  • Evaluate the change of the 8-point WHO COVID19 disease severity scale on day 15 and 30
  • Evaluate the change of the 8-point WHO COVID19 disease severity scale on day 15 in the subgroup of patients with a baseline neutralizing antibody titer (PRNT50) <80
  • Evaluate the effect of 300ml convP on mortality in patients admitted to the ICU
  • Evaluate the effect of 300ml plasma therapy on hospital days for patients admitted to the ICU within 24 hours after admission
  • Evaluate the impact of plasma therapy on the decrease in SARS-CoV2 shedding from airways
  • Evaluate the difference in effect of convP on mortality in patients with a duration of symptoms < or > the median duration of symptoms in the study population
  • Evaluate the impact of CTL and NK cell immunity on the likelihood of being protected from immune serum transfer
  • Safety of convP therapy
  • Evaluate the impact of covP on long-term lung function

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 426 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This trial is a randomized comparative trial. Patients will be randomized between the infusion of 300mL of convP versus the standard of care.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Convalescent Plasma Therapy From Recovered Covid-19 Patients as Therapy for Hospitalized Patients With Covid-19
Actual Study Start Date : April 8, 2020
Estimated Primary Completion Date : July 1, 2020
Estimated Study Completion Date : July 1, 2020

Arm Intervention/treatment
Experimental: Convalescent plasma
Standard of care plus 300mL of convalescent plasma from COVID-19 recovered donors
Biological: Convalescent plasma

Infusion of plasma retrieved from donors with a history of PCR proven symptomatic COVID.

Plasma will be administered according to the Erasmus MC KIS protocol regarding the use of blood products


No Intervention: Standard of care
standard of care (supportive care, oxygen, antibiotics)



Primary Outcome Measures :
  1. Overall mortality until discharge from the hospital or a maximum of 60 days after admission whichever comes first [ Time Frame: until hospital discharge or a maximum of 60 days whichever comes first ]
    the mortality in the 300ml convP group will be compared with the control arm


Secondary Outcome Measures :
  1. Impact of 300ml convP therapy on hospital days [ Time Frame: until hospital discharge or a maximum of 60 days whichever comes first ]
    the hospital days in the 300ml convP group will be compared with the control arm

  2. Impact of 300ml convP on weaning from oxygen therapy [ Time Frame: until hospital discharge or a maximum of 60 days whichever comes first ]
    A patient will be considered weaned from oxygen therapy when the patient did not receive oxygen for at least 24 hours.

  3. Impact of 300ml convP on overall mortality in patients admitted to the ICU within 24 hours after admission [ Time Frame: until hospital discharge or a maximum of 60 days whichever comes first ]
    the overall mortality in hospital days in patients admitted tot the ICU within 24 hours after admission in the 300ml convP group will be compared with the patients admitted tot the ICU within 24 hours after admission in the control arm

  4. Difference in the effect of convP on mortality in patients with a duration of symptoms less or more the median duration of symptoms in the study population [ Time Frame: hospital discharge or a maximum of 60 days whichever comes first ]
    The mortality in patients with a duration of symptoms less than the median duration of symptoms in the study population will be compared with the mortality in patients with a duration of symptoms more than the median duration of symptoms in the study population

  5. Impact of 300ml convP therapy on ICU days in patients admitted to the ICU within 24 hours after admission [ Time Frame: Until hospital discharge, estimated average 4 weeks ]
    the ICU days in hospital days in patients admitted to the ICU within 24 hours after admission in the 300ml convP group will be compared with the patients admitted tot the ICU within 24 hours after admission in the control arm

  6. Impact of plasma therapy on the decrease in SARS-CoV2 shedding from airways [ Time Frame: until hospital discharge, estimated average 2 weeks ]
    airway samples will be taken on day 1 - 3 - 5 - 7 - 10 - 14 - and at discharge

  7. Impact of CTL and NK cell immunity on the likelihood of being protected from immune serum transfer [ Time Frame: until hospital discharge, extimated average 2 weeks ]
    Blood wil be drawn at day 1, day 7 and day 14

  8. Safety of convP therapy [ Time Frame: until hospital discharge or a maximum of 60 days whichever comes first ]
    Evaluation of Severe Adverse Events and transfusion related adverse events

  9. Change of the 8-point WHO COVID19 disease severity scale on day 15 [ Time Frame: until day 15 ]
    The WHO COVID19 disease severity scale on day 15 will be compared with the WHO COVID19 disease severity scale on day 1

  10. Change of the 8-point WHO COVID19 disease severity scale on day 30 [ Time Frame: until day 30 ]
    The WHO COVID19 disease severity scale on day 30 will be compared with the WHO COVID19 disease severity scale on day 1 and day 15

  11. Change of the 8-point WHO COVID19 disease severity scale on day 15 in the subgroup of patients with a baseline neutralizing antibody titer (PRNT50) <80. [ Time Frame: until day 15 ]
    The WHO COVID19 disease severity scale on day 15 will be compared with the WHO COVID19 disease severity scale on day 1 in patients with a baseline neutralizing antibody titer (PRNT50) <80.

  12. Impact of plasma therapy on risk of long-term structural lung damage and lung function [ Time Frame: up to 12 months after plasma transfusion ]
    Low dose CT and lung function is done 6 weeks after discharge and if abnormal again 3 months after discharge.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with PCR confirmed COVID disease
  • Admitted to the hospital
  • The most recent PCR positive sample is <96hrs old
  • Written informed consent by patient or legal patient representative
  • Age at least 18 years

Exclusion Criteria:

  • Participation in another intervention trial on the treatment of COVID-19 that falls under the Dutch law human research (WMO) and in which individual patients are randomized to different treatment options
  • Known IgA deficiency
  • Invasive ventilation for already >96 hours

Donors: Eligibility for plasma donation

Inclusions Criteria:

  • A history of COVID infection that was documented by PCR
  • Known ABO-Resus(D) blood group
  • A screening for irregular antibodies with a titer ≤ 1:32
  • Asymptomatic for at least 14 days
  • Written informed consent regarding the plasmapheresis procedure
  • Tested negative for HIV, HBV, HCV, HEV, HTLV and syfilis

Exclusion Criteria:

  • Age <18 years and > 65 years
  • Weight <50kg
  • Medical history of heart failure
  • History of transfusion with red blood cells, platelets or plasma
  • History of organ- or tissue transplant
  • A cumulative stay in the United Kingdom of ≥ 6 months in the period between 01-01-1980 and 31-12-1996
  • A history of i.v. drug use
  • Insulin dependent diabetes
  • An underlying severe chronic illness (i.e. history of heart failure, cancer or stroke)
  • Tested positive for HLA- or HNA-antibodies

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04342182


Contacts
Layout table for location contacts
Contact: Bart Rijnders, MD, PhD +31107033510 b.rijnders@erasmusmc.nl

Locations
Show Show 18 study locations
Sponsors and Collaborators
Erasmus Medical Center
Sanquin Plasma Products BV
Investigators
Layout table for investigator information
Principal Investigator: Bart Rijnders, MD, PhD Erasmus Medical Center
Layout table for additonal information
Responsible Party: Bart Rijnders, MD, PhD, Erasmus Medical Center
ClinicalTrials.gov Identifier: NCT04342182    
Other Study ID Numbers: NL73489.078.20
First Posted: April 10, 2020    Key Record Dates
Last Update Posted: May 18, 2020
Last Verified: May 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No